Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration

American Journal of Kidney Diseases

Volumn 45, Issue 2, 2005, Pages 360-371

  Swart, Eleonora L ^a   De Jongh, Joost ^b   Zuideveld, Klaas P ^b   Danhof, Meindert ^b   Thijs, Lambertus G ^b   Strack Van Schijndel, Robert J M ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Hemofiltration; Intensive care; Lorazepam; Midazolam; Pharmacokinetics

Indexed keywords

1 HYDROXYMIDAZOLAM; 1 HYDROXYMIDAZOLAM GLUCURONIDE; 4 HYDROXYMIDAZOLAM; 4 HYDROXYMIDAZOLAM GLUCURONIDE; CELLULOSE TRIACETATE; DRUG METABOLITE; GLUCURONIDE; LORAZEPAM; LORAZEPAM GLUCURONIDE; MIDAZOLAM; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLOOD FLOW; BLOOD SAMPLING; CELL MEMBRANE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; COVARIANCE; CRITICAL ILLNESS; DILUTION; DRUG CLEARANCE; FEMALE; FLOW MEASUREMENT; HEMOFILTRATION; HUMAN; INTENSIVE CARE; MALE; METABOLITE; PLASMA PROTEIN BINDING; ULTRAFILTRATION;

EID: 15944387369     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2004.09.004     Document Type: Article

References (27)

1. J.J. Driessen, T.B. Vree, P.J.M. Guelen The effects of acute changes in renal function on the pharmacokinetics of midazolam during long-term infusion in ICU patients Acta Anaesth Belg 42 1991 149 155
2. H. Allonen, G. Ziegler, U. Klotz Midazolam kinetics Clin Pharmacol Ther 30 1981 653 661
3. J.W. Mandema, B. Tuk, A.L. van Steveninck, D.D. Breimer, A.F. Cohen, M. Danhof Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers Clin Pharmacol Ther 51 1992 715 728
4. R. Amrein, W. Hetzel Pharmacology of Dormicum (midazolam) and Anexate (flumazenil) Acta Anaesthesiol Scand 34 suppl 92 1990 S6 S15
5. T.M. Bauer, R. Ritz, C. Haberthür Prolonged sedation due to accumulation of conjugated metabolites of midazolam Lancet 346 1995 145 147
6. R.M. Arendt, D.J. Greenblatt, D.C. Liebisch, M.D. Luu, S.M. Paul Determinants of benzodiazepine brain uptake Lipophilicity versus binding affinity Psychopharmacology 93 1987 72 76
7. R. Boulieu, B. Lehmann, F. Salord, C. Fisher, D. Morlet Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients Eur J Drug Metab Pharmacokinet 23 1998 255 258
8. G.R. Park, E. Miller What changes drug metabolism in critically ill patients?--III. Effect of pre-existing disease on the metabolism of midazolam Anaesthesia 51 1996 431 434
9. H.R. Vinik, J.G. Reves, D.J. Greenblatt, D.R. Abernethy, L.R. Smith The pharmacokinetics of midazolam in chronic renal failure patients Anesthesiology 59 1983 390 394
10. R. Calvo, E. Suárez, J.M. Rodríguez-Sasiain, I. Martíinez The influence of renal failure on the kinetics of intravenous midazolam An "in vitro" and "in vivo" study Res Commun Chem Pathol Pharmacol 78 1992 311 320
11. D.J. Greenblatt, R.I. Shader, K. Franke Pharmacokinetics and bioavailability of intravenous, intramuscular and oral lorazepam in humans J Pharm Sci 68 1979 57 63
12. R.K. Verbeeck, T.B. Tjandramaga, R. Verberckmoes, P.J. de Schepper Biotransformation and excretion of lorazepam in patients with chronic renal failure Br J Clin Pharmacol 3 1976 1033 1039
13. G. Morrison, S.T. Chiang, H.H. Koepke, B.R. Walker Effect of renal impairment and hemodialysis on lorazepam kinetics Clin Pharmacol Ther 35 1984 646 652
14. J.F. Bugge Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients Acta Anaesthesiol Scand 45 2001 929 934
15. F. Bressolle, J.M. Kinowski, J.E. de la Coussaye, N. Wynn, J.J. Eledjam, M. Galtier Clinical pharmacokinetics during continuous haemofiltration Clin Pharmacokinet 26 1994 457 471
16. R. Bellomo, C. Ronco Continuous renal replacement therapy in the intensive care unit Intensive Care Med 25 1999 781 789
17. L. Aaltonen, J. Kanto, M. Salo Cerebrospinal fluid concentrations and serum protein binding of lorazepam and its conjugate Acta Pharmacol Toxicol 46 1980 156 158
18. A.A. Vletter, A.G.L. Burm, L.T.M. Breimer, J. Spierdijk High performance liquid chromatographic assay to determine midazolam and flumazenil simultaneously and individually in human plasma J Chromatogr Biomed Appl 530 1990 177 185
19. B. Efron Bootstrap methods Another look at the Jacknife Ann Stat 7 1979 1 26
20. J.W. Dundee, P.S. Collier, R.J.T. Carlisle, K.W. Harper Prolonged midazolam elimination half-life Br J Clin Pharmacol 21 1986 425 429
21. A. Kassai, G. Toth, M. Eichelbaum, U. Klotz No evidence of a genetic polymorphism in the oxidative metabolism of midazolam Clin Pharmacol 15 1988 319 325
22. R.J. Wills, K.C. Khoo, P.P. Soni, I.H. Patel Increased volume of distribution prolongs midazolam half-life Br J Clin Pharmacol 29 1990 269 272
23. Y. Duguay, C. Baar, F. Skorpen, C. Guillemette A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity Clin Pharmacol Ther 75 2004 223 233
24. A. Vermes, T.R.A. Math, I.H. van der Sijs, J. Dankert, H.J. Guchelaar Population pharmacokinetics of flucytosine Comparison and validation of three models using STS, NPEM, and NONMEM Ther Drug Monit 22 2000 676 687
25. E.L. Swart, K.P. Zuideveld, J. de Jongh, M. Danhof, L.G. Thijs, R.M.J. Strack van Schijndel Comparative population pharmacokinetics of lorazepam and midazolam upon long-term administration in critically ill patients Br J Clin Pharmacol 57 2004 135 145
26. R.K. Verbeeck, T.B. Tjandramaga, P.J. de Schepper, R. Verberckmoes Impaired elimination of lorazepam following subchronic administration in two patients with renal failure Br J Clin Pharmacol 12 1981 749 751
27. M. Bolon, O. Bastien, C. Flamens, S. Paulus, R. Boulieu Midazolam disposition in patients undergoing continuous venovenous hemodialysis J Clin Pharmacol 41 2001 959 962